SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.83 CNY | -1.49% |
|
-1.46% | +3.57% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,526 | 14,112 | 10,008 | 14,014 | 14,514 | - | - |
| Enterprise Value (EV) 1 | 15,526 | 14,112 | 10,008 | 14,014 | 14,514 | 14,514 | 14,514 |
| P/E ratio | -47.6 x | -31.3 x | -21.6 x | -48.6 x | -87 x | 166 x | 32.1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 561 x | 74.1 x | - | 36.3 x | 19.5 x | 10.8 x | 6.7 x |
| EV / Revenue | 561 x | 74.1 x | - | 36.3 x | 19.5 x | 10.8 x | 6.7 x |
| EV / EBITDA | -57.6 x | -34.1 x | - | -56.2 x | -96.9 x | 105 x | 25.8 x |
| EV / FCF | -38.7 x | -26.9 x | - | -47.4 x | -62.4 x | -39.9 x | -63.7 x |
| FCF Yield | -2.59% | -3.72% | - | -2.11% | -1.6% | -2.51% | -1.57% |
| Price to Book | 9.6 x | 11.5 x | - | 8.58 x | 9.89 x | 9.33 x | 7.23 x |
| Nbr of stocks (in thousands) | 240,000 | 240,000 | 240,000 | 264,708 | 264,708 | - | - |
| Reference price 2 | 64.69 | 58.80 | 41.70 | 52.94 | 54.83 | 54.83 | 54.83 |
| Announcement Date | 2/25/21 | 2/23/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 27.66 | 190.4 | - | 386.4 | 742.8 | 1,347 | 2,167 |
| EBITDA 1 | -269.7 | -414.2 | - | -249.5 | -149.7 | 138.2 | 563.6 |
| EBIT 1 | -304.8 | -459 | - | -297.8 | -170.7 | 100.6 | 513.5 |
| Operating Margin | -1,102.02% | -241.14% | - | -77.06% | -22.98% | 7.47% | 23.7% |
| Earnings before Tax (EBT) 1 | -304.8 | -465.1 | - | -299.1 | -173 | 98.79 | 512 |
| Net income 1 | -319.2 | -451 | -462 | -278.6 | -165.6 | 87.46 | 451.8 |
| Net margin | -1,154.08% | -236.92% | - | -72.09% | -22.29% | 6.49% | 20.86% |
| EPS 2 | -1.360 | -1.880 | -1.930 | -1.090 | -0.6300 | 0.3300 | 1.708 |
| Free Cash Flow 1 | -401.5 | -525.4 | - | -295.3 | -232.4 | -363.6 | -227.8 |
| FCF margin | -1,451.64% | -275.98% | - | -76.43% | -31.29% | -27% | -10.52% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/25/21 | 2/23/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -402 | -525 | - | -295 | -232 | -364 | -228 |
| ROE (net income / shareholders' equity) | -19.9% | -29.1% | - | -20% | -11.4% | 5.51% | 21.9% |
| ROA (Net income/ Total Assets) | -27.9% | -22.2% | - | -12.2% | -5.3% | 4.3% | 14.8% |
| Assets 1 | 1,145 | 2,030 | - | 2,278 | 3,124 | 2,034 | 3,063 |
| Book Value Per Share 2 | 6.740 | 5.130 | - | 6.170 | 5.540 | 5.880 | 7.580 |
| Cash Flow per Share 2 | -1.430 | -1.890 | - | -0.8800 | -0.8400 | -0.2300 | 1.620 |
| Capex 1 | 57.7 | 70.7 | - | 62.6 | 21.1 | 316 | 461 |
| Capex / Sales | 208.53% | 37.16% | - | 16.2% | 2.83% | 23.47% | 21.28% |
| Announcement Date | 2/25/21 | 2/23/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
54.83
CNY
Average target price
64
CNY
Spread / Average Target
+16.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.57% | 2B | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 688266 Stock
- Financials Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
